Challenges in the codevelopment of companion diagnostics
The goal of personalized medicine, to effectively customize diagnosis, treatment and prevention of disease to one's genetic composition, is one that has been known and sought for many years. Increasingly, molecular companion diagnostics based on one's inherited or somatic biomarkers are desired to ensure the effective, safe develop ment and application of a personalized drug. This has been reflected in several recent guid ance documents from regulatory organizations worldwide, and in a number of instances, the use of a companion diagnostic has been required or recommended prior to administration of a personalized therapeutic.
There have been a number of successes in personalized medicine, but not as many as one might expect based on the historical level of interest [1] . Proposed regulatory documents have attempted to address this shortfall, and in doing so have identified the drug-diagnostic codevelopment process as critical to the success of personalized medicine. Unfortunately, the codevelopment process poses several challenges. Potential barriers are: a relatively low probability of success after a scientific discovery is made; navigating various development objectives for different drugs, targeting appropriate markets and users; the lack of clear regulatory and policy guidance; and partnership challenges between research and diagnostic cultures. Consequently, pharmaceutical and diagnostic companies may be less motivated to invest the substantial amount of time and resources needed to create a successful personalized therapeutic.
The promise & power of personalized medicine
The field of personalized medicine evolved from the discipline of pharmacogenetics, essentially expanding upon the goal of identifying the right treatment, at the right dose, for the right disease/ patient [2, 3] . Utilizing a stratified approach and identifying groups of patients based on certain biologic characteristics or biomarkers has the potential to be more efficient and effective while reducing undesirable drug interactions and side effects [4] .
Recently, the interest in personalized medi cine has increased substantially. From a 2011 PubMed search using the term 'personalized medicine', the number of scientific publications on the subject showed an exponential growth in the period 1999-2010, from approximately 0-5 to 450, respectively [4] . In 2006, there were 13 prominent examples of personalized medi cine drugs, treatments and diagnostics products available [101] ; in 2011, that number increased to 72 [102] .
The personalized medicine market in the USA was estimated to be US$232 billion in 2009 [103] . The core diagnostic and therapeutic segment of the market comprised primarily of pharma ceutical, medical device and diagnostics compa nies was estimated at US$24 billion and expected to grow by 10% annually, reaching US$42 bil lion by 2015 [103] . More evidence of a growing interest in personalized medicine is detailed in Table 1 . In addition, molecular diagnostics repre sents one of the fastest growing segments of the Therapeutics harnessing the power of personalized medicine have the potential to revolutionize healthcare. Companion diagnostics are critical to this goal and are increasingly relied upon to ensure the effective, safe development and use of a personalized therapeutic. Companion diagnostics are the focus of several recent regulatory guidance documents; the drug-diagnostic codevelopment process has become increasingly relevant and necessary. Despite this, the promise of companion diagnostics has not been fully realized and there are multiple difficulties that still need resolution. The path to codevelop a successful companion diagnostic with its complementary drug is complex, fragmented and fraught with several challenges. In this article, we discuss the logistic, strategic business, regulatory and financial challenges involved in drug-companion diagnostic codevelopment.
future science group Review Moore, Babu & Cotter US$37 billion US market for in vitro diagnostics (IVDs) [103] . Even with this growth potential, approximately only 1% of marketed therapeutics had a companion diagnostic in 2011 [104] . Even after considering that companion diagnostics are not appropriate for all therapeutics, this percent age is lower than one would expect based upon interest documented in the market research. This suggests the difficulty of developing a successful companion diagnostic.
Companion diagnostics & how they impact personalized medicine
Successful companion diagnostics have been used in several modalities (box 1). One use is to stratify patients who will (or will not) respond to a particular drug prior to its administration, or identify those who should not be treated with the drug because of a high risk for adverse events [5] . For example, FISH ana lysis of the ALK gene rearrangements is required to select patients for treatment with the oral ALK inhibitor crizo tinib (Xalkori ® ) in nonsmallcell lung cancer (NSCLC) [6] [7] [8] . Specifically in onco logy, predic tive biomarkers can address aspects of host toxic ity or of direct anticancer efficacy (by monitoring treatment effectiveness) [9] . For example, quan titative realtime PCR ana lysis of BCR-ABL1 fusion transcripts is used to monitor imatinib mesylate (Gleevec ® ) treatment in patients with chronic myeloid leukemia [10] .
Another important use of companion diagnos tics is to customize drug dosage based on metabo lism biomarker status, such as in warfarin dos ing. Individuals with CYP2C9*2 and CYP2C9*3 genotypes produce an enzyme with reduced capac ity (by 30 and 80%, respectively) to metabolize warfarin [5] . Those with VKORC1 1639G>A genotypes produce an enzyme with approximately 50% reduced metabolism capa city. Dosing using traditional methods can lead to delayed and ele vated systemic warfarin levels, often leading to an increased bleeding risk [11] . As such, reduced war farin dosages may be recommended for those with specific genotypes. Although not the standard of care, warfarin dosage can be calculated after strati fication using a molecular companion diagnostic and algorithm incorporating a patient's CYP2C9 and VKORC1 genotypes [105] , and estimating the therapeutic dose in patients new to warfarin [12] .
Regulatory responses
Recent regulatory agency commentaries acknowl edge the value of companion diagnostics and the slow output of personalized thera peutics from pharmaceutical companies. The US FDA, Health Canada and the EMA have either mandated or recommended in several cases that biomarker Percentage of marketed drugs with a companion diagnostic in 2011 1%
[104]
Percentage of marketed drugs that inform or recommend genetic testing for optimal treatment 10%
[114]
Number of pharmacogenomic biomarkers that are included on US-FDA approved drug labels 33 [114] Portion of all treatments in late clinical development that rely on biomarker data 30% [115] Portion of all treatments in early clinical development that rely on biomarker data 50% [115] Portion of all treatments in preclinical development that rely on biomarker data 60% [115] Amount of all biopharmaceutical companies surveyed that require all compounds in development to have a biomarker in 2011 30% [104] Percentage increase in personalized medicine investment by industry over the last 5 years 75% Challenges in the codevelopment of companion diagnostics Review testing be performed prior to prescribing certain drugs [102] . While this opinion was consistent between the regulatory agencies, documents still lacked clear guidance about how to navigate the numerous steps in the d evelopment process.
A February 2011 revision of the European Commission's directive on IVDs indicated, "…the competence of the European Medicine Agency should be extended to pharmacogenom ics, as the IVD medical device has an impact on the health outcome of the medicinal product and then the analytical and clinical validity of the IVD medical device should be part of the assess ment of the benefit-risk assessment of the medici nal product" [106] . The importance of companion diagnostics was reiterated here, but again without clear recommendations about their development.
Subsequently, in July 2011, the FDA issued draft guidance for comment purposes on the development of IVD companion diagnostic devices. The draft guidance indicated that: "The results of the IVD companion diagnostic device will be essential for the safe and effective use of the therapeutic product and its use will be stipulated in the labeling of the therapeutic product." It was noted that: "With some excep tions [the] FDA does not believe it may approve a novel therapeutic product or new therapeu tic product indication for use with an IVD companion diagnostic if the IVD companion diagnostic is not approved or cleared for that indication" [107] .
The FDA draft guidance also recommended that: "In most circumstances, if use of an IVD companion diagnostic device is essential for the safe and effective use of a therapeutic product, [it and its] therapeutic product should be approved or cleared contemporaneously by [the] FDA for the use indicated in the therapeutic product labeling" [107] . This was a clear statement from a regulatory agency that it may not approve a product unless its companion diagnostic was also approved or cleared, emphasizing the need for codevelopment. Furthermore, the document helpfully outlined the codevelopment steps in a flow diagram; it also suggested various pathways that might be taken. Unfortunately, guidance documents that only apply to a small subset of cases in the per sonalized genomics field also hinder its progress. Fortunately, in late 2011, the FDA declared an intent to produce guidances on enrichment strate gies in clinical drug develop ment [108] , so further clarification should be forthcoming.
There are several examples of required com panion diagnostics. The original example, from 1998, is in the oncology sector. Detection of HER2/neu protein amplification by a molecu lar cytogenetic companion diagnostic is used to identify patients more likely to respond to trastu zumab (Herceptin ® ) in breast (and now gastric) cancers [13] [14] [15] [16] .
In late 2011, Health Canada required the use of a companion diagnostic to identify patients with metastatic melanoma containing the V600E mutation in the BRAF gene [17] [18] [19] [20] , prior to treatment with vemurafenib (Zelboraf ® ). The commentary reiterated that: "The para llel development of this companion diagnostic together with a specific targeted therapy marks a new era of personalized health care in which patients are selected for treatment on the basis of well validated molecular biomarkers" [18] .
A 2007 example outside the oncology sec tor is with the use of maraviroc (Selzentry ® ) in patients with HIV/AIDS. A highly sensitive tropism assay is required to identify those with CCR5tropism HIV1, who are then candi dates for maraviroc, in conjunction with other retroviral agents [21, 22] .
In these cases, companion diagnostics were deemed critical for appropriate stratification of patients before drug administration. More examples are detailed in Table 2 .
Developing a companion diagnostic
The components required to create a compan ion diagnostic are outlined in Figure 1 . Many of these require specific expertise and experience, from early scientific discovery and biomarker develop ment, to regulatory filing and approval, and finally manufacturing.
Drug-diagnostic codevelopment
The key to effectively introduce a success ful personalized therapeutic to a market is co development of the drug and its companion diagnostic. Ideally, a companion diagnostic will be studied in parallel with its drug in Phase I or II [23] . This scenario is not always possible, due to safety of a drug being tested prior to its efficacy. Challenges in the codevelopment of companion diagnostics Review
In addition, companion diagnostic develop ment may not always be useful until some time has gone by in the drug discovery period. Guidance documents from multiple regulatory agencies have attempted to outline the steps in the creation of companion diagnostics, and the complexity of the drug-diagnostic codevelopment process. In June 2010, the EMA issued a reflection paper to outline suggested steps involved in the codevelopment of a new pharmacogenomic b iomarker and the relevant assay(s) [109] .
In its 2011 draft guidance, the FDA expanded on this to say: "Ideally, a therapeutic product and its corresponding IVD companion diagnostic device would be developed contemporaneously, with the clinical performance and clinical signi ficance of the IVD companion diagnostic device established using data from the clinical develop ment program of the corresponding therapeutic product…" [107] . Suggested codevelopment steps are outlined in Figure 2 . Unfortunately, no guid ance document is explicit on how this process should be implemented.
Traditional partners for drug development & approval
Outsourcing options for pharmaceutical compa nies are widely available and commonly utilized 
Challenges in companion diagnostic codevelopment
The components of companion diagnostic develop ment require specific expertise rarely found in a single organization, introducing sev eral challenges. These are compounded by the fact that an effective companion diagnostics co development process does not currently exist, or is rudimentary at best. Key challenges fall into four broad categories (Figure 3) . Challenges in the codevelopment of companion diagnostics Review revenue; the choice of an assay platform also affects deployment into, and acceptance by, the end user clinical laboratories that may offer the test in the market. A recent example illustrates challenges related to business partnerships. Rearrangements of the ALK gene have been reported in patients with NSCLC [8, 24] . Patients with advanced NSCLC containing ALK rearrangements show a posi tive response to ALKtargeted therapy (crizo tinib [Xalkori]) [6] [7] [8] , while patients without the ALK rearrangement showed a poor response thus making the companion diagnostic to identify ALK rearrangements essential to drug administration.
As The Wall Street Journal reported, co development of Xalkori and its companion diagnostic was strategically problematic [25] . Pfizer (the drug's developer and manufacturer) partnered with the diagnostics company Abbott Molecular to develop a molecular companion diagnostic to analyze ALK in tumor tissue. Researchers between the companies reportedly had difficulties working together early on, which hampered initial development. In addition, Abbott Molecular reportedly resisted Pfizer's request to train commercial clinical laboratories in advance of FDA approval because: "It was concerned that those trained would forget how to conduct the assay while waiting for the drug and test to go on sale" [25] . Abbott Molecular may have delayed training because it did not want to risk an expenditure of resources prior to an FDA approval. Ultimately, Xalkori and its companion diagnostic test kit were granted FDA approval simultaneously, but not before several delays and difficulties were experienced in the process. The ALK companion diagnostic (a FISHbased assay) has an advantage in that it utilizes a technology that can be performed in many laboratories.
Pharmaceutical and diagnostic companies have partnered successfully. But as with business partnerships outside the personalized medicine field, they need to be robust -particularly regard ing trust, harmonized goals and clear communi cation at all levels -to help ensure a successful outcome.
n Regulatory challenges As noted previously, the CRO's expertise is in operational efficiency of clinical trials for pharma ceuticals. This clinical trial experience may be attractive to pharmaceutical companies looking to outsource this function, but few CROs have experience in IVD development, manufacture and medical device (companion diagnostic) validation trials, as well as experience in navigating regulatory recommendations and requirements.
Pharmaceutical companies want to ensure that clinical trials conducted for develop ment of a companion diagnostic are run in an environ ment that ensures quick translation to the clinical setting after marketing launch. Delays may be introduced because of regulatory requirements. Therefore, many are turning to appropriately licensed and accredited clinical laboratories. This necessitates partnering with a laboratory possessing and maintaining those credentials and regulatory consulting expertise, which many traditional diagnostics companies and CROs do not offer.
n Financial challenges Codevelopment of a therapeutic and companion diagnostic is associated with uncertainty and risk. Utilizing extensive new biologic tests increases the complexity and cost of the drug development process [26] . Unlike the pharmaceutical develop ment industry, where there is an understanding that a large number of potential drugs will fail clinical studies (and that revenues will be derived from a very small cohort of successful drugs), no such precedent currently exists in the diagnostic development space. While the codevelopment of a diagnostic and therapeutic is advantageous from a cost and efficiency perspective, the number of latestage compound failures is high. This makes a codevelopment agreement even less financially desirable from a diagnostic perspective, due to the significant risk and high cost involved in devel oping diagnostics for drugs that never receive regulatory approval. Thus, diagnostic companies may be hesitant to share the financial burden and partner for companion diagnostic development.
In addition, end users such as physicians and other healthcare providers have expressed Review Moore, Babu & Cotter discomfort with companion diagnostics direct ing their medical recommendations and treat ment plans [111] . This can limit the financial suc cess of the drug and its corresponding companion diagnostic, due to low usage.
Current diagnostic reimbursement policies do not support the development of highvalue molecular tests [26] , as reimbursement of these tests has typically been based on cost, not value (or potential value) [27] .
Payers also may not support their use because they conclude that there is not enough evidence to prove efficacy. Despite the FDA's 2007 rec ommendation for genotyping for all patients being prescribed warfarin, in April 2009 the US Centers for Medicare and Medicaid Services (CMS) decided not to routinely reimburse for companion diagnostics needed to help physi cians correctly dose warfarin [23, 112, 113] . CMS claimed there was not enough evidence to prove that use of the tests improves patients' health [23] . Furthermore, some payers may not re imburse for a companion diagnostic even when it is recom mended by a regulatory agency like the FDA, and have expressed doubts about the clinical usefulness of many companion diagnostics [23] .
To overcome some of these issues, some authors have suggested that companies devel oping companion diagnostics use a strategy of royal ties associated with the sales of the therapeutics their tests target [111] .
Regulatory agencies can also be engaged to enhance personalized medicine development. It has been suggested that creating incentives com parable to the Orphan Drug Act for personalized medicines that target relatively small populations might boost development [23] . In addition, the FDA is attempting to coordinate and clarify the development process that manufacturers should follow, including delineating when a companion diagnostic must be approved before or c oncurrently with approval of the t herapy [23] .
It has also been recommended that medical professional societies in corporate evidencebased testing in their clinical practice guidelines, which may facilitate the understanding and institution alization of personalized medicine [23] . These can also help guide payers and help them gain con fidence in personalized therapeutics, which will in turn, increase their development.
n Logistical challenges Specialized scientific expertise is required from the initial steps in biomarker discovery, optimization, and through to validation. Few pharma ceutical companies have this expertise in house, therefore, outsourcing becomes necessary. Many major pharmaceutical companies includ ing Roche, Pfizer, Merck, AstraZeneca, Bristol Myers Squibb, Amgen, Biogen and Eli Lilly have chosen, or needed, to partner with exter nal companies to develop their own compan ion diagnostics [28] . Many of these companies have selected large partners in the diagnostics industry. While outsourcing has been necessary, doing so introduced several logistical challenges when coordinating the efforts of multiple part ners. It also fragmented the process resulting in disorganization and miscommunications.
Overall, pharmaceutical companies must overcome several logistical complexities when Challenges in the codevelopment of companion diagnostics Review managing and coordinating multiple partners in the process: research and development (ini tial research and biomarker development), a diagnostics company (to develop and possibly manufacture an assay kit), a CRO (to conduct validation trials), regulatory personnel and clini cal laboratories (to perform assay validation and trial testing). All of these steps have the potential to result in product delay and i ntroduce points of inefficiency (Figure 4) .
Biopharma brings half of the solution

Contract diagnostics organization
One way for pharmaceutical companies to mitigate logistical challenges related to out sourcing is to bring key scientific expertise within their companies. However, significant time and resources are required on the scientific research and development side of personalized
Executive summary
The promise & power of personalized medicine
Stratified medicine can be more effective than traditional medicine. There are growing scientific, medical and economic interests in personalized medicine.
Companion diagnostics & how they impact personalized medicine
Companion diagnostics are critical to personalized medicine to ensure the effective, safe development and application of a personalized drug. Companion diagnostics can be used to diagnose, select treatment, dose treatment and monitor treatment of disease. Companion diagnostic development is challenging and requires specific expertise in several areas.
Regulatory responses
Several regulatory guidances have either mandated or recommended that biomarker testing be performed prior to prescribing certain drugs.
There are several companion diagnostics currently required by regulatory agencies.
Developing a companion diagnostic
Efficiently introducing a successful personalized therapeutic to market requires codevelopment of the drug and its companion diagnostic. Regulatory agencies have attempted to describe the codevelopment process, but it is still rudimentary at best. 
Challenges to drug-diagnostic codevelopment
An integrated approach is the solution
A new, streamlined business model for codevelopment is necessary. The number of partners needs to be reduced, with each containing services in house. Services could include clinical research, clinical laboratory services, manufacturing and consulting.
Conclusion
Companion diagnostics are necessary for personalized medicine, but not easy to develop. Regulatory agencies have weighed in and recommended drug-diagnostic codevelopment, although no effective process currently exists.
Several challenges make the current codevelopment process very difficult, and more work is needed in this area. An integrated business model offers solutions to streamline the drug-diagnostic codevelopment process.
Future perspective
Companion diagnostics will be increasingly critical to the success of personalized medicine in many medical specialties. Therapeutics and companion diagnostic codevelopment will continue to be a challenge, but will be mitigated by new paradigms such as the availability of integrated outsourcing options.
future science group Review Moore, Babu & Cotter therapeutics, potentially leading to several dead ends before success is achieved. As such, some pharmaceutical companies may find bringing expertise in house hard to justify. New busi ness models are developing that offer this and other expertise in house, in efforts to partner with pharmaceutical companies seamlessly and reduce these logistical challenges.
Integration is the solution
As suggested by Cohen et al.: "To improve pros pects for personalized medicine, more evidence is needed, but also better integration and code velopment of drugs and companion diagnos tics" [23] . Expeditious coordination of the drugdiagnostic codevelopment process requires a robust, lean and streamlined business model. The number of partners in the process should be as few as possible. Ideally, all services (clini cal research, clinical laboratory, manu facturing, consulting), could be contained within one organization. Scientific expertise in house can carry the process from biomarker discovery to clinical research, to clinical laboratory services, to manufacturing, and finally to the market. This allows the process to be objective, nimble and able to create any assay and follow the right regulatory pathway from the beginning. This business model is illustrated in Figure 5 .
Conclusion
The combination of advances in molecular medicine, regulatory guidances, rational thera peutics use and the need for cost containment in healthcare is advancing the goal of true personal ized medicine. Integral to the achievement of this objective will be the widespread implement ation of companion diagnostics. The increasing importance of companion diagnostics and the need for codevelopment with therapeutics has many challenges. However, the application of new paradigms, such as flexible and integrated outsourcing options for companion diagnos tics, will ensure a viable future for p ersonalized medicine.
Future perspective
To date, the clearest advancement of personal ized medicine has primarily been within the field of oncology. Companion diagnostics are criti cal to the future of personalized drug develop ment, and the codevelopment process will be the focus of future regulatory guidances and studies. Although an understanding of the underlying molecular pathways in conditions such as neuro psychiatric disorders (e.g., Alzheimer's disease), endocrine disorders (e.g., diabetes) and cardio vascular disease is incomplete; future work is being done to identify challenges in these areas, to help further the application of personalized medicine in these fields [29] .
In order for drug-diagnostic codevelopment to be successful, coordination between multi ple agencies, stakeholders and groups will be essential. This requires successful relationships between those in public and private enterprises. In addition, ongoing communication between drug developers and regulatory agencies needs to occur to inform and progress regulatory g uidance development.
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